Cellular Mechanism of Newly Synthesized Indoledione Derivative-induced Immunological Death of Tumor Cell
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: EY-6 is one of the newly synthesized indoledione derivatives to induce tumor cell-specific cell death. In this study, we investigated the mechanism of immunological death induced by EY-6 at mouse colon cancer cell as well as at the normal immune cell represented by dendritic cell. Methods: C57BL/6 mouse syngeneic colon cancer cell MC38 was treated with EY-6, and analyzed by MTT for viability test, flow cytometry for confirming surface expressing molecules and ELISA for detection of cytokine secretion. Normal myeloid-dendritic cell (DC) was ex vivo cultured from bone marrow hematopoietic stem cells of C57BL/6 mice with GM-CSF and IL-4 to analyze the DC uptake of dead tumor cells and to observe the effect of EY-6 on the normal DC. Results: EY-6 killed the MC38 tumor cells in a dose dependent manner (25, 50 and 100μM) with carleticulin induction. And EY-6 induced the secretion of IFN-γ but not of TNF-α from the MC38 tumor cells. EY-6 did not kill the ex-vivo cultured DCs at the dose killing tumor cells and did slightly but not significantly induced the DC maturation. The OVA-specific cross-presentation ability of DC was not induced by chemical treatment (both MHC II and MHC I-restricted antigen presentation). Conclusion: Data indicate that the EY-6 induced tumor cell specific and immunological cell death by modulation of tumor cell phenotype and cytokine secretion favoring induction of specific immunity eliminating tumor cells.
Abstract
Background: EY-6 is one of the newly synthesized indoledione derivatives to induce tumor cell-specific cell death. In this study, we investigated the mechanism of immunological death induced by EY-6 at mouse colon cancer cell as well as at the normal immune cell represented by dendritic cell. Methods: C57BL/6 mouse syngeneic colon cancer cell MC38 was treated with EY-6, and analyzed by MTT for viability test, flow cytometry for confirming surface expressing molecules and ELISA for detection of cytokine secretion. Normal myeloid-dendritic cell (DC) was ex vivo cultured from bone marrow hematopoietic stem cells of C57BL/6 mice with GM-CSF and IL-4 to analyze the DC uptake of dead tumor cells and to observe the effect of EY-6 on the normal DC. Results: EY-6 killed the MC38 tumor cells in a dose dependent manner (25, 50 and 100μM) with carleticulin induction. And EY-6 induced the secretion of IFN-γ but not of TNF-α from the MC38 tumor cells. EY-6 did not kill the ex-vivo cultured DCs at the dose killing tumor cells and did slightly but not significantly induced the DC maturation. The OVA-specific cross-presentation ability of DC was not induced by chemical treatment (both MHC II and MHC I-restricted antigen presentation). Conclusion: Data indicate that the EY-6 induced tumor cell specific and immunological cell death by modulation of tumor cell phenotype and cytokine secretion favoring induction of specific immunity eliminating tumor cells.
참고문헌 (19)
- Obeid M, "Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic", Cancer Res, 67, pp.7941~7944 (2007)
- Galon J, "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome", Science, 313, pp.1960~1964 (2006)
- Apetoh L, "Immunogenicity of anthracyclines: moving towards more personalized medicine", Trends Mol Med, 14, pp.141~151 (2008)
- Zitvogel L, "Immunological aspects of cancer chemotherapy", Nat Rev Immunol, 8, pp.59~73 (2008)
- Chan OT, "The immunological effects of taxanes", Cancer Immunol Immunother, 49, pp.181~185 (2000)
- Spreafico F, "Cancer chemotherapeutics as immunomodulators", Springer Semin Immunopathol, 8, pp.361~374 (1985)
- North RJ, "Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells", J Exp Med, 155, pp.1063~1074 (1982)
- Nowak AK, "Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy", Cancer Res, 62, pp.2353~2358 (2002)
- Suzuki E, "Gemcitabine selectively eliminates splenic Gr-1+", CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity, 2005, pp.11, 6713~6721
- Machiels JP, "Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte", macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2, Cancer Res, pp.2001, 61[DOI]
- Zitvogel L, "Immunogenic tumor cell death for optimal anticancertherapy: the calreticulin exposure pathway", Clin Cancer Res, 16, pp.3100~3104 (2010)
- Panaretakis T, "Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death", EMBO J, 28, pp.578~590 (2009)
- Obeid M, "Calreticulin exposure dictates the immunogenicity of cancer cell death", Nat Med, 13, pp.54~61 (2007)
- 유충규, "Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B", Akt, 200612, pp.16, 6001~6005[DOI]
- imidazole- 4,7-diones as inhibitor of endothelial cell proliferation, "Bioorg Med Chem", 2006, 5795~501
- -phenazine-5,12-diones and evaluation of their cytotoxicity and DNA topoisomerase II inhibitory activity, "BIOORGANIC MEDICINAL CHEMISTRY", 2007, 451~457, pp.PERGAMON-ELSEVIER SCIENCE LTD
- Seo JM, "JM91, a newly synthesized indoledione derivative, inhibits rat aortic vascular smooth muscle cells proliferation and cell cycle progression through inhibition of ERK1", 2 and Akt activations, 2008, pp.75, 1331~1340[DOI]
- Esumi N, "Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression", Cancer Res, 51, pp.1185~1189 (1991)
- Janelidze S, "Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas", J Immunother, 32, pp.593~601 (2009)